Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.46 |
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8195208 | 0.88 | BACE1 (0.44) | BACE1PGRBACE2ARCTSD | |
| SCHEMBL12410393 | 0.85 | BACE1 (0.41) | BACE1PGRBACE2ARCTSD | |
| SCHEMBL2173248 | 0.82 | BACE1 (0.43) | BACE1PGRBACE2ARCTSD | |
| SCHEMBL8266532 | 0.82 | PGR (0.35) | BACE1PGRBACE2NPY5ROPRM1 | |
| SCHEMBL7538407 | 0.81 | BACE1 (0.58) | BACE1PGRBACE2ARCTSD | |
| SCHEMBL8267865 | 0.81 | MAOA (0.37) | BACE1NPY5R | |
| SCHEMBL12410382 | 0.81 | BACE1 (0.43) | BACE1PGR | |
| SCHEMBL8267868 | 0.81 | OPRD1 (0.40) | OPRM1 | |
| SCHEMBL10329056 | 0.81 | BACE1 (0.47) | BACE1PGRBACE2ARCTSD | |
| SCHEMBL12410378 | 0.80 | BACE1 (0.38) | BACE1PGRBACE2CTSDNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885PGR 1172/4885BACE2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.